2026/6/8 13:54:04
Major Milestone: Affinity’s Legubicin for Injection Granted FDA Orphan Drug Designation, Ushering in a New Chapter for Soft Tissue Sarcoma Treatment
Company Overview
Affinity (Shanghai) Biopharmaceutical Co., Ltd. (“Affinity”) was founded in Zhangjiang, Shanghai in 2012. Dedicated to addressing the toxicity challenges of conventional chemotherapy and targeted therapies while focusing on unmet clinical needs in oncology, it is a China-rooted, globally oriented biopharmaceutical enterprise independently developing first-in-class novel anti-cancer drugs.
With its proprietary TMEA technology platform, Affinity strategically focuses on two breakthrough therapeutic modalities: XDC and IO. The company is committed to delivering transformative oncology therapies with reduced toxicity, enhanced efficacy, and inherent potential for synergistic combination use.
Partnerships
Affinity aims to become a fully integrated, innovative biopharmaceutical company, and establishing broad partnerships is a core pillar of our strategy.
News
Affinity (Shanghai) Biopharmaceutical Co., Ltd.
Email: admin@affinity.net.cn
R&D and Business Development Cooperation: bd@affinity.net.cn
PR ：pr@affinity.net.cn
Address: 3rd Floor, Building 1, No. 368 Zhangjiang Road, Pudong New Area, Shanghai, China